within Pharmacolibrary.Drugs.ATC.C;

model C01CX07
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.00031666666666666665,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.125,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 12.0,            
    Vdp             = 0.214,
    k12             = 85,
    k21             = 85
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C01CX07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Xamoterol is a selective β1-adrenoceptor partial agonist used for the management of heart failure. It exerts positive inotropic and chronotropic effects while having a mild sympathomimetic activity. It was evaluated primarily in the 1980s and early 1990s for heart failure but is not in current clinical use or approved in most countries today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers after a single oral dose.</p><h4>References</h4><ol><li><p>Bastain, W, Boyce, MJ, Stafford, LE, Morton, PB, Clarke, DA, &amp; Marlow, HF (1988). Pharmacokinetics of xamoterol after intravenous and oral administration to volunteers. <i>European journal of clinical pharmacology</i> 34(5) 469–473. DOI:<a href=&quot;https://doi.org/10.1007/BF01046704&quot;>10.1007/BF01046704</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2904884/&quot;>https://pubmed.ncbi.nlm.nih.gov/2904884</a></p></li><li><p>Sorensen, EV, Faergeman, O, Day, M, &amp; Bastain, W (1988). Pharmacokinetics of xamoterol after intravenous and oral administration to patients with chronic heart failure. <i>European journal of clinical pharmacology</i> 35(2) 183–185. DOI:<a href=&quot;https://doi.org/10.1007/BF00609250&quot;>10.1007/BF00609250</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2903827/&quot;>https://pubmed.ncbi.nlm.nih.gov/2903827</a></p></li><li><p>Nicholls, DP, Taggart, AJ, McCann, JP, Bastain, W, &amp; Shanks, RG (1989). The pharmacokinetics of xamoterol in liver disease. <i>British journal of clinical pharmacology</i> 28(6) 718–721. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.1989.tb03566.x&quot;>10.1111/j.1365-2125.1989.tb03566.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2532923/&quot;>https://pubmed.ncbi.nlm.nih.gov/2532923</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C01CX07;
